

## Therapeutic Class Overview

### Attention-Deficit/Hyperactivity Disorder (ADHD) Agents

#### INTRODUCTION

- Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder among children, with an estimated prevalence of up to 10% of school-age children in the United States (U.S.). It is more common in boys than girls and frequently persists into adulthood (*Feldman et al 2014*). Epidemiologic studies of adult ADHD have estimated the current prevalence to be 4.4% in the U.S. (*Bukstein 2017*).
  - In children, this chronic disorder is characterized by symptoms of hyperactivity, impulsivity, and/or inattention. These symptoms affect cognitive, academic, behavioral, emotional, and social functioning (*Krull 2017a*). Common comorbid psychiatric disorders include oppositional defiant disorder, conduct disorder, depression, anxiety disorder, and learning disabilities (*Krull 2017b*). Approximately 20% of children with ADHD develop chronic tic disorders and approximately 50% of children with chronic tics or Tourette syndrome have comorbid ADHD (*Krull 2017c*).
  - ADHD in adults is characterized by symptoms of inattention, impulsivity, and restlessness. Impairment in executive function and emotional dysregulation frequently occur. Common comorbid psychiatric disorders include mood and anxiety disorders, substance use disorder, and intermittent explosive disorder (*Bukstein 2017*).
- For children < 17 years of age, the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) diagnosis of ADHD requires ≥ 6 symptoms of hyperactivity and impulsivity or ≥ 6 symptoms of inattention. For adolescents ≥ 17 years of age and adults, ≥ 5 symptoms of hyperactivity and impulsivity or ≥ 5 symptoms of inattention are required.
  - The symptoms of hyperactivity/impulsivity or inattention must occur often; be present in more than 1 setting; persist for at least 6 months; be present before the age of 12 years; impair function in academic, social, or occupational activities; and be excessive for the developmental level of the child.
  - Other physical, situational, or mental health conditions that could account for the symptoms must be excluded.
- Treatment of ADHD may involve behavioral/psychologic interventions, medication, and/or educational interventions, alone or in combination (*Krull 2017d*).
  - For preschool children (age 4 through 5 years), behavioral therapy is considered the first-line treatment; when medication is necessary, methylphenidate is generally recommended.
  - For children and adolescents with moderate to severe ADHD, medication and behavioral therapy are recommended. In general, stimulants are the first-line agents; however, nonstimulant medications may be more appropriate for certain children
    - About 30% of patients do not respond to or may not tolerate the initial stimulant treatment. At least one-half of children who do not respond to one type of stimulant will respond to the other. If there is still no improvement, consideration should be given to switching to or adding a non-stimulant ADHD medication (*Pharmacist's Letter 2015, Krull 2017e*).
- Multiple agents are currently approved by the Food and Drug Administration (FDA) for the treatment of ADHD. They include central nervous system (CNS) stimulants (amphetamine- and methylphenidate-based formulations), as well as non-stimulants: a selective norepinephrine reuptake inhibitor (SNRI), atomoxetine, and 2 alpha<sub>2</sub>-adrenergic agonists, clonidine extended-release (ER) and guanfacine ER.
  - Due to the potential for abuse, the stimulant agents are classified as Schedule II controlled substances.
  - Several stimulants are also approved for the treatment of narcolepsy and exogenous obesity; the use of stimulants for the treatment of obesity will not be covered in this review. Lisdexamfetamine dimesylate is the only FDA-approved drug for the treatment of binge eating disorder (BED).

**Table 1. Medications Included Within Class Review**

Drug	Generic Availability
<b>Stimulants</b>	
Evekeo (amphetamine sulfate)	-
Adderall (mixed amphetamine salts)	✓
Focalin (dexmethylphenidate hydrochloride [HCl])	✓
ProCentra (dextroamphetamine sulfate)	✓
Zenzedi (dextroamphetamine sulfate)	✓

Data as of June 23, 2017 AVD/CME

Page 1 of 16

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Drug	Generic Availability
Desoxyn (methamphetamine HCl)	✓
methylphenidate HCl chewable tablets	✓
Methylin Oral Solution (methylphenidate HCl)	✓
Ritalin (methylphenidate HCl)	✓
Dexedrine Spansule (dextroamphetamine sulfate sustained-release)	✓
Metadate ER (methylphenidate HCl ER)	✓
Adzenys XR-ODT (amphetamine ER)	-
Dyanavel XR (amphetamine ER)	✓
Adderall XR (mixed amphetamine salts ER)	✓
Mydayis (mixed amphetamine salts ER)	-
Focalin XR (dexmethylphenidate HCl ER)	✓
Vyvanse (lisdexamfetamine dimesylate)	-
Aptensio XR (methylphenidate HCl ER)	-
Concerta (methylphenidate HCl ER)	✓
Cotempla XR-ODT (methylphenidate ER)	-
Metadate CD (methylphenidate HCl ER)	✓
methylphenidate HCl extended-release	✓
QuilliChew ER (methylphenidate HCl ER)	-
Quillivant XR (methylphenidate HCl ER)	-
Ritalin LA (methylphenidate HCl ER)	✓
Daytrana (methylphenidate transdermal system)	-
<b>Non-stimulants</b>	
Strattera (atomoxetine HCl)	✓
Kapvay (clonidine HCl ER)	✓
Intuniv (guanfacine HCl ER)	✓

Note: Branded generic Dexedrine (dextroamphetamine sulfate) has been discontinued, but some product may still be available.

(*Drugs @FDA 2017, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations 2017*)

**INDICATIONS**

**Table 2. Food and Drug Administration Approved Indications**

Indication	Evekeo (amphetamine sulfate)	Adzenys XR-ODT, Dyanavel XR (amphetamine sulfate ER)	Adderall (mixed amphetamine salts)	Adderall XR, Mydayis (mixed amphetamine salts ER)	Strattera (atomoxetine HCl)	Kapvay (clonidine HCl ER)	Focalin (dexamethylphenidate IR); Focalin XR (dexamethylphenidate ER)	ProCentra, Zenzedi (dextroamphetamine sulfate IR); Dexedrine Spansule (dextroamphetamine sulfate SR)	Intuniv (guanfacine HCl ER)	Vyvanse (lisdexamfetamine dimesylate)	Desoxyn (methamphetamine HCl)	Methylphenidate HCl (IR); methylphenidate HCl chewable tablets; Metadate ER (methylphenidate ER)	Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Metadate CD, QuillChew ER, Quillivant XR, Ritalin LA (methylphenidate ER)
ADHD*		✓	✓	✓	✓		✓			✓			✓
ADHD, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, and social) for a stabilizing effect in pediatric patients with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal electroencephalogram (EEG) may or may not be present, and a diagnosis of CNS dysfunction may or may not be warranted.*	✓							✓			✓	✓	
Treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications						✓			✓				
Narcolepsy**	✓		✓					✓				✓	
Exogenous obesity, as a short term (a few weeks) adjunct in a regimen	✓										✓		

Indication	Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Metadate CD, QuilliChew ER, Quillivant XR, Ritalin LA (methylphenidate ER)	Methylin Oral Solution, Ritalin (methylphenidate HCl IR); methylphenidate HCl chewable tablets; Metadate ER (methylphenidate ER)	Desoxyn (methamphetamine HCl)	Vyvanse (lisdexamfetamine dimesylate)	Intuniv (guanfacine HCl ER)	ProCentra, Zenzedi (dextroamphetamine sulfate IR); Dexedrine Spansule (dextroamphetamine sulfate SR)	Focalin (dexamethylphenidate IR); Focalin XR (dexamethylphenidate ER)	Kapvay (clonidine HCl ER)	Strattera (atomoxetine HCl)	Adderall XR, Mydayis (mixed amphetamine salts ER)	Adderall (mixed amphetamine salts)	Adzenys XR-ODT, Dyanavel XR (amphetamine sulfate ER)	Evekeo (amphetamine sulfate)
of weight reduction based on caloric restriction for patients refractory to alternative therapy (eg, repeated diets, group programs, and other drugs). <sup>†</sup>													
Moderate to severe BED in adults											✓		

(Prescribing Information: Adderall 2016, Adderall XR 2017, Adzenys XR-ODT 2017, Aptensio XR 2017, Concerta 2017, Cotempla 2017, Daytrana 2017, Desoxyn 2017, Dexedrine Spansule 2017, Dyanavel XR 2017, Evekeo 2016, Focalin 2017, Focalin XR 2017, Intuniv 2016, Kapvay 2016, Mydayis 2017, Metadate CD 2017, Methylin Oral Solution 2016, methylphenidate chewable tablets 2015; methylphenidate ER 2015; ProCentra 2017, QuilliChew ER 2017, Quillivant XR 2017, Ritalin 2017, Ritalin LA 2017, Strattera 2017, Vyvanse 2017, Zenzedi 2017)

\* Adderall, Evekeo, ProCentra, and Zenzedi are approved for use in children 3 years of age and older. Daytrana, Desoxyn, Dexedrine Spansule, Dyanavel XR, Intuniv, and Kapvay are approved for use in children 6 years of age and older. Adderall XR, Adzenys XR-ODT, Aptensio XR, Focalin, Focalin XR, Metadate CD, Metadate ER, Methylin Oral Solution, methylphenidate chewable tablets, QuilliChew ER, Quillivant XR, Ritalin, Ritalin LA, Strattera, and Vyvanse are approved for use in patients 6 years of age and older. Cotempla XR-ODT is approved for use in pediatric patients 6 to 17 years of age. Concerta is approved for use in children 6 years of age and older, adolescents, and adults up to 65 years of age. Mydayis is approved for use in patients 13 years of age and older.

\*\*These drugs are approved for use in patients 6 years of age and older.

†These drugs are not recommended for use in children under 12 years of age for treatment of exogenous obesity. The limited usefulness of these products should be weighed against possible risks inherent in use of the drugs.

- Limitation of use:
  - Lisdexamfetamine: Lisdexamfetamine is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular (CV) adverse events (AEs). The safety and effectiveness of this drug for the treatment of obesity have not been established.
  - Mydayis: Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of AEs, mainly insomnia and decreased appetite.
- Information on indications, mechanism of action, pharmacokinetics, dosing, and safety has been obtained from the prescribing information for the individual products, except where noted otherwise.

## CLINICAL EFFICACY SUMMARY

- Randomized trials, systematic reviews, and meta-analyses have found stimulants, atomoxetine, and alpha<sub>2</sub>-adrenergic agonists to be more efficacious than placebo in reducing the core symptoms of ADHD in children and adolescents.
  - Cotelpla XR-ODT, a new methylphenidate ER orally disintegrating tablet formulation, was approved based on a randomized, double-blind (DB), multi-center (MC), placebo-controlled (PC) laboratory classroom study (*Childress et al 2017*) (N = 87) which found that the average Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP)-Combined score was significantly better for Cotelpla XR-ODT than for placebo (least squares [LS] mean 14.3 [95% CI, 12.2 to 16.4] vs. 25.3 [9% CI, 23.0 to 27.6], respectively, p < 0.0001).
  - Mydayis, a new mixed amphetamine salts product, was approved for the treatment of ADHD based on the results of 5 unpublished MC, DB, PC, randomized controlled trials (RCTs): 3 in adults and 2 in pediatric patients 13 to 17 years of age. The studies found that Mydayis demonstrated a statistically significant treatment effect compared with placebo on various ADHD outcomes measures (eg, ADHD-Rating Scale [ADHD-RS] score, Permanent Product Measure of Performance [PERMP] score) (*Mydayis Prescribing Information 2017*) (see results below in Table 3 below).

**Table 3. Summary of Primary Efficacy Results for Mydayis**

Study Number (Age range)	Primary Endpoint	Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline	Placebo-subtracted Difference (95% CI)
<b>Adult Studies</b>					
Study 1 (18 to 55 years)	ADHD-RS	Mydayis 12.5 mg/day <sup>§</sup>	39.8 (6.38)	-18.5	-8.1 (-11.7 to -4.4)
		Mydayis 37.5 mg/day <sup>§</sup>	39.9 (7.07)	-23.8	
		Placebo	40.5 (6.52)	-10.4	
Study 2 (18 to 55 years)	Average PERMP	Mydayis 50 mg/day <sup>§</sup>	239.2 (75.6) <sup>†</sup>	293.23*	18.38 (11.28 to 25.47)
		Placebo	249.6 (76.7) <sup>†</sup>	274.85*	
Study 3 (18 to 55 years)	Average PERMP	Mydayis 25 mg/day <sup>§</sup>	217.5 (59.6) <sup>†</sup>	267.96*	19.29 (10.95 to 27.63)
		Placebo	226.9 (61.7) <sup>†</sup>	248.67*	
<b>Pediatric Studies</b>					
Study 4 (13 to 17 years) <sup>‡</sup>	ADHD-RS-IV	Mydayis 12.5 to 25 mg/day <sup>§</sup>	36.7 (6.15)	-20.3	-8.7 (-12.6 to -4.8)
		Placebo	38.3 (6.67)	-11.6	
Study 5 (13 to 17 years)	Average PERMP	Mydayis 25 mg/day <sup>§</sup>	214.5 (87.8) <sup>†</sup>	272.67*	41.26 (32.24 to 50.29)
		Placebo	228.7 (101) <sup>†</sup>	231.41*	

SD= standard deviation; LS = least squares; CI = confidence interval

<sup>†</sup>Pre-dose PERMP total score

\*LS mean for PERMP is post-dose average score over all sessions of the treatment day, rather change from baseline

<sup>‡</sup>Results are for a subgroup of study 4 and not the total population

<sup>§</sup>Doses statistically significant for placebo

- A systematic (Cochrane) review of 185 RCTs (*Storebø et al 2015*) (N = 12,245) in children and adolescents with ADHD found that methylphenidate may improve teacher-rated ADHD symptoms, teacher-reported general behavior, and parent-reported quality of life (QOL) vs. placebo. However, the evidence was of low quality.
- An RCT called the Preschool ADHD Treatment Study (PATS) (*Greenhill et al 2006*) evaluated the efficacy of methylphenidate immediate-release (IR) in 303 preschool children with ADHD and found that it demonstrated significant reductions on ADHD symptom scales; however, the effect sizes (0.4 to 0.8) were smaller than those generally reported for school-age children.
- A systematic (Cochrane) review of 23 PC, RCTs (*Punja et al 2016*) (N = 2675) found that amphetamines were effective at improving the core symptoms of ADHD, but they were also associated with a higher risk of AEs compared to placebo. There was no evidence that one kind of amphetamine was better than another and there was no difference between short-acting and long-acting formulations.



- A meta-analysis of 25 DB, PC, RCTs (*Schwartz et al 2014*) (N = 3928) in children and adolescents with ADHD found atomoxetine to be superior to placebo for overall ADHD symptoms, with a medium effect size (-0.64).
- A meta-analysis of 12 RCTs (*Hirota et al 2014*) (N = 2276) in pediatric patients with ADHD found that alpha<sub>2</sub>-adrenergic agonists were significantly superior to placebo for overall ADHD symptoms both as monotherapy and, to a lesser extent, as augmentation therapy to stimulants.
  - Meta-analytic results failed to demonstrate a significant difference in efficacy between alpha<sub>2</sub>-adrenergic agonists. In sub-analyses of individual formulations, the ER formulations separated robustly from placebo whereas the IR formulations did not separate from placebo.
- A systematic review of 16 RCTs and 1 meta-analysis (*Chan et al 2016*) (N = 2668) found evidence supporting the use of methylphenidate and amphetamine ER formulations, atomoxetine, and guanfacine ER for the treatment of ADHD in adolescents. For the primary outcome measure of mean change in ADHD-RS total symptom score, both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 points.
- For the treatment of ADHD in children and adolescents, stimulants typically have a slightly larger treatment effect size (standardized mean difference [SMD]) than non-stimulants (approximately 1.0 vs. approximately 0.7 for both atomoxetine and alpha<sub>2</sub>-adrenergic agonists). However, there is insufficient evidence to definitively conclude that one stimulant is more efficacious than another (*Krull 2017e, AAP 2011*).
  - An Agency for Healthcare Research and Quality (AHRQ) review of 78 studies (*Jadad et al 1999*) evaluating the efficacy of various interventions for the treatment of ADHD in children and adults found few, if any, differences between methylphenidate and dextroamphetamine.
  - A meta-analysis of 23 DB, PC trials (*Faraone 2010a*) comparing the efficacy of methylphenidate and amphetamine formulations found that amphetamine products may be moderately more efficacious than methylphenidate products.
  - A DB, PC, RCT (*Newcorn et al 2008*) (N = 516) comparing the efficacy of atomoxetine vs. methylphenidate ER (osmotic-release formulation) in patients 6 to 16 years of age with ADHD found that both drugs were superior to placebo in terms of response rate, and that methylphenidate ER was superior to atomoxetine.
  - A meta-analysis of 29 DB, PC trials (*Faraone et al 2006*) evaluated the efficacy of various medications (methylphenidate and amphetamine compounds, atomoxetine, pemoline [no longer available in the U.S.], bupropion, and modafinil) for the treatment of ADHD. The effect sizes for non-stimulant medications were significantly less than those for IR stimulants or long-acting stimulants. The 2 classes of stimulant medications did not differ significantly from one another.
  - A meta-analysis of 28 DB, PC, RCTs (*Stuhec et al 2015*) (N = 4699) compared the efficacy of various medications for the treatment of ADHD in children and adolescents. Efficacy in reducing ADHD symptoms compared to placebo was small for bupropion (SMD = -0.32; 95% confidence interval [CI], -0.69 to 0.05), modest for atomoxetine (SMD = -0.68; 95% CI, -0.76 to -0.59) and methylphenidate (SMD = -0.75; 95% CI, -0.98 to -0.52), and highest for lisdexamfetamine (SMD = -1.28; 95% CI, -1.84 to -0.71).
  - A study (*Li et al 2016*) evaluating the efficacy of treatments for ADHD (atomoxetine, bupropion, clonidine, guanfacine ER, lisdexamfetamine, methylphenidate) in children and adolescents found that lisdexamfetamine had the highest efficacy, while methylphenidate had the lowest incidence of AEs and ranked second in ADHD-RS scores and third in Conners' Parent Rating Scale-Revised (CPRS) scores. Atomoxetine had the lowest rate of all-cause withdrawals, but its efficacy was lower than that of clonidine, guanfacine ER, lisdexamfetamine, and methylphenidate.
- Alpha<sub>2</sub>-adrenergic agonists have been associated with improvements in ADHD symptoms and comorbid tics.
  - A meta-analysis of 9 DB, PC, RCTs (*Bloch et al 2009*) (N = 477) was conducted to determine the relative efficacy of different medications in treating ADHD and tic symptoms in children with both Tourette syndrome and ADHD.
  - Methylphenidate seemed to offer the greatest improvement of ADHD symptoms and did not seem to worsen tic symptoms.
  - Alpha<sub>2</sub>-adrenergic agonists offered the best combined improvement in both tic and ADHD symptoms.
  - Atomoxetine significantly improved both tic and ADHD severity compared to placebo.
  - One small study found that tic severity was significantly increased with higher doses of dextroamphetamine treatment.
- There are limited efficacy data regarding the treatment of ADHD in the adult population. Comparison of effect sizes in clinical trials suggests that stimulant medications are more efficacious in adult ADHD than non-stimulants.
  - In a meta-analysis of 12 clinical trials (*Cunill et al 2009*) (N = 3375) comparing atomoxetine with placebo in adult ADHD, atomoxetine led to a modestly greater reduction in ADHD symptom severity, but was associated with higher all-cause discontinuation.
  - A meta-analysis (*Faraone 2010b*) of 19 randomized trials of 13 medications for adult ADHD found a greater average effect size for reduction in ADHD symptoms in patients receiving short- and long-acting stimulant medications (vs.

placebo; 0.86 and 0.73, respectively) compared with patients receiving non-stimulant medication (vs. placebo; 0.39). No difference in effect size was found between short- and long-acting stimulants.

- Lisdexamfetamine dimesylate has demonstrated efficacy in the treatment of BED. Direct comparison trials between lisdexamfetamine and other drugs used off-label to treat BED are lacking.
  - In 2 Phase 3, 12-week, randomized, DB, PC trials (*McElroy et al 2016*) (N = 773) in patients with moderate to severe BED, lisdexamfetamine-treated patients had a statistically significantly greater reduction from baseline in mean number of binge days per week at week 12 vs. placebo (treatment difference in study 1: -1.35 [-1.70 to -1.01]; study 2: -1.66 [-2.04 to -1.28]; both p < 0.001).
    - A 12-month, open-label extension study (*Gasior et al 2017*) (N = 599) in adults with BED found that the long-term safety and tolerability of lisdexamfetamine were generally consistent with the safety profile observed in 3 previous short-term trials in BED as well as its established profile for ADHD. Common treatment-emergent AEs included dry mouth, headache, insomnia, and upper respiratory tract infection. Weight loss and increases in blood pressure and pulse rate were also observed.
  - A systematic review and meta-analysis of 9 waitlist-controlled psychological trials and 25 PC trials evaluating pharmacologic (n = 19) or combination (n = 6) treatment for BED (*Brownley et al 2016*) found that therapist-led cognitive behavioral therapy (CBT), lisdexamfetamine, and second-generation antidepressants (SGAs) increased binge-eating abstinence (relative risk [RR], 4.95 [95% CI, 3.06 to 8.00], 2.61 [CI, 2.04 to 3.33], and 1.67 [CI, 1.24 to 2.26], respectively), while lisdexamfetamine and SGAs decreased binge-eating frequency (mean difference in days/week, -1.35 [CI, -1.77 to -0.93] and -0.67 [CI, -1.26 to -0.09], respectively). Topiramate and other forms of CBT also increased abstinence and reduced binge-eating frequency.

## CLINICAL GUIDELINES

### ADHD

- Several clinical guidelines have provided recommendations on the treatment of ADHD in children and adolescents.
  - According to the American Academy of Pediatrics (AAP) guidelines (2011), the evidence is particularly strong for stimulant medications, and sufficient but less strong for atomoxetine, guanfacine ER, and clonidine ER (in that order). Guanfacine ER and clonidine ER have evidence to support their use as adjunctive therapy with stimulant medications. Methylphenidate is recommended for preschool-aged children who have had an inadequate response to behavioral interventions.
  - The American Academy of Child and Adolescent Psychiatry (AACAP) guidelines (*Pliszka et al 2007*) state that both methylphenidate and amphetamines are equally efficacious in the treatment of ADHD. The long-acting formulations are equally efficacious as the IR formulations and may be used as initial therapy. Short-acting stimulants are often used as initial treatment in small children (< 16 kg in weight), for whom there are no long-acting preparations in a sufficiently low dose. Some patients may respond similarly to different stimulant classes, whereas other patients may respond preferentially to only 1 of the classes of stimulants. Although stimulants have demonstrated greater efficacy compared to atomoxetine in published studies, atomoxetine may be used first-line in patients with an active substance abuse problem, comorbid anxiety or tics, and in those who experience severe AEs with stimulants.
  - The Medical Letter (2015) recommends that treatment of ADHD in school-age children or adults should begin with an oral stimulant, either a methylphenidate- or amphetamine-based formulation. Mixing short- and long-acting stimulants can be helpful to achieve an immediate effect for early-morning school classes or for reducing rebound irritability or overactivity, especially in the evening. An ER alpha<sub>2</sub>-adrenergic agonist may be helpful as adjunctive therapy with a stimulant in patients who cannot tolerate usual doses of the stimulant, particularly those with tics. Atomoxetine is an alternative for patients who cannot tolerate stimulants or for whom treatment with a controlled substance is undesirable.
  - The AACAP practice parameter for the treatment of children and adolescents with tic disorders (2013) states that alpha<sub>2</sub>-adrenergic agonists have demonstrated an effect size of 0.5 for the amelioration of tics and may be preferred by some prescribers over antipsychotics due to their relatively favorable AE profile.

### Narcolepsy

- The American Academy of Sleep Medicine (AASM) practice parameters (*Morgenthaler et al 2007*) recommend various drugs for the treatment of daytime sleepiness due to narcolepsy including modafinil (high degree of clinical certainty); amphetamine, methamphetamine, dextroamphetamine, and methylphenidate (moderate degree of clinical certainty); sodium oxybate (high degree of clinical certainty); and selegiline (uncertain clinical certainty).

### BED

- According to the American Psychiatric Association (APA) practice guidelines on eating disorders (Yager et al 2006, Yager et al 2012 [guideline watch update]), treatment of BED may include the following:
  - Nutritional rehabilitation and counseling
  - Psychosocial treatment
    - CBT, behavior therapy, dialectical behavior therapy (DBT), and interpersonal therapy (IPT) have all been associated with binge frequency reduction rates of 67% or more and significant abstinence rates during active treatment.
    - Self-help programs using self-guided, professionally designed manuals have been effective in reducing the symptoms of BED in the short-run for some patients and may have long-term benefit.
  - Medications
    - Antidepressant treatment is associated with short-term reductions in binge-eating but generally does not result in substantial weight loss. Selective serotonin reuptake inhibitors (SSRIs) have the fewest difficulties with AEs and the most evidence for efficacy when used at the high end of the recommended dose range.
    - Topiramate can reduce bingeing and decrease weight, but its use may be limited by AEs.
  - Combination psychotherapy and pharmacotherapy
    - For most patients, adding antidepressant therapy to a behavioral weight control and/or CBT regimen does not have a significant effect on binge suppression.
    - Although limited evidence is available, combined treatment is frequently used in clinical practice.
- The Task Force on Eating Disorders of the World Federation of Societies of Biological Psychiatry (Aigner et al 2011) concluded that for the treatment of BED, grade A evidence supports the use of imipramine (moderate risk-benefit ratio), sertraline (good risk-benefit ratio), citalopram/escitalopram (good risk-benefit ratio), orlistat (low to moderate risk-benefit ratio), and topiramate (moderate risk-benefit ratio). Atomoxetine has grade B evidence supporting its use.

#### SAFETY SUMMARY

- Due to the potential for abuse, the stimulants are classified as Schedule II controlled substances. Atomoxetine, clonidine ER, and guanfacine ER are not classified as controlled substances.
- Various stimulants are contraindicated for use in patients with advanced arteriosclerosis, symptomatic CV disease, moderate to severe hypertension, hyperthyroidism, hypersensitivity to sympathomimetic amines, glaucoma, agitated states, history of drug abuse, tics, and in those using monoamine oxidase inhibitors (MAOIs). The stimulants carry a boxed warning for potential drug abuse and dependence. They also have warnings for increased risks of serious CV reactions, psychiatric AEs, suppression of growth, peripheral vasculopathy, and priapism. Amphetamines have a warning for risk of serotonin syndrome when used in combination with other drugs affecting the serotonergic neurotransmitter systems.
  - Common AEs of stimulants include anorexia, decreased weight, tachycardia, anxiety, irritability, and insomnia.
  - Refer to the prescribing information for details on warnings, precautions, and AEs for individual products. For example:
    - QuilliChew ER can be harmful to patients with phenylketonuria (PKU) since it contains phenylalanine.
    - Because the Concerta tablet is nondeformable and does not appreciably change in shape in the gastrointestinal tract, it should not ordinarily be administered to patients with preexisting severe gastrointestinal narrowing.
    - The use of Daytrana may result in chemical leukoderma and contact sensitization; in addition, exposure of the application site to external heat sources should be avoided due to increased absorption of the drug.
- Atomoxetine is contraindicated for use in patients with glaucoma, pheochromocytoma, severe CV disorders, hypersensitivity to any component of the product, and in those taking MAOIs. It carries a boxed warning for rare increased risk of suicidal ideation in children and adolescents. It also has warnings for serious CV events, effects on blood pressure and heart rate, effects on growth, psychiatric AEs, rare cases of severe liver injury, and priapism.
  - Common AEs associated with atomoxetine include somnolence, nausea, and vomiting.
- The alpha<sub>2</sub>-adrenergic agonists are contraindicated in patients known to be hypersensitive to any constituent of the product. They carry warnings for increased risk of hypotension, bradycardia, and syncope; sedation and somnolence; rebound hypertension; and cardiac conduction abnormalities.
  - Common AEs associated with clonidine ER include somnolence, fatigue, and irritability while common AEs with guanfacine ER include somnolence, fatigue, and hypotension.



**DOSING AND ADMINISTRATION**
**Table 4. Dosing and Administration**

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
<b>Stimulants</b>					
Evekeo (amphetamine)	4 to 6 h	Tablets	Oral	<i>ADHD, narcolepsy:</i> Daily up to divided doses daily  <i>Exogenous obesity:</i> Divided doses daily	<i>ADHD and narcolepsy</i> The first dose should be given upon awakening; additional doses at intervals of 4 to 6 hours.
Adzenys XR-ODT (amphetamine ER)	10 to 12 h	Orally disintegrating tablets	Oral	Daily in the morning	As soon as the blister pack is opened, the tablet should be placed on the patient's tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed.
Dyanavel XR (amphetamine ER)	Up to 13 h	Suspension	Oral	Daily in the morning	The bottle should be shaken before administration.
Adderall (mixed amphetamine salts)	4 to 6 h	Tablets	Oral	<i>ADHD, narcolepsy:</i> Daily up to divided doses daily	The first dose should be given on awakening, then additional doses at intervals of 4 to 6 hours.
Adderall XR (mixed amphetamine salts ER)	10 to 12 h	Capsules	Oral	Daily in the morning	Capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce and consumed immediately. The dose of a single capsule should not be divided.
Mydayis (mixed	16 h	Capsules	Oral	Daily in the morning	Dosage adjustment

Data as of June 23, 2017 AVD/CME

Page 9 of 16

This information is considered confidential and proprietary to OptumRx. It is intended for internal use only and should be disseminated only to authorized recipients. The contents of the therapeutic class overviews on this website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Clinicians should refer to the full prescribing information and published resources when making medical decisions.

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
amphetamine salts (ER)					is needed for severe renal impairment. Use in ESRD is not recommended.  Capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce and consumed immediately in its entirety without chewing. The dose of a single capsule should not be divided.
Focalin (dexmethylphenidate)	5 to 6 h	Tablets	Oral	Twice daily	
Focalin XR (dexmethylphenidate ER)	10 to 12 h	Capsules	Oral	Daily in the morning	ER capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce.
ProCentra, Zenzedi (dextroamphetamine)	4 to 6 h	Solution (ProCentra) Tablets (Zenzedi)	Oral	<u>ADHD, narcolepsy</u> : Daily up to divided doses daily	The first dose should be given upon awakening; additional doses at intervals of 4 to 6 hours
Dexedrine Spansule (dextroamphetamine SR)	6 to 8 h	Capsules	Oral	<u>ADHD</u> Daily or twice daily  <u>Narcolepsy</u> Daily	
Vyvanse (lisdexamfetamine)	10 to 12 h	Capsules, chewable tablets	Oral	<u>ADHD, BED</u> : Daily in the morning	Dosage adjustment is needed for renal impairment/ESRD.  The capsules may be swallowed whole or can be opened, emptied, and mixed with yogurt, water, or orange juice and consumed

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					<p>immediately. A single capsule should not be divided.</p> <p>The chewable tablets must be chewed thoroughly before swallowing. A single dose should not be divided.</p>
Desoxyn (methamphetamine)	3 to 5 h	Tablets	Oral	<p><i>ADHD</i>: Daily to twice daily</p> <p><i>Obesity</i>: 30 min before each meal</p>	
Methylin, Ritalin (methylphenidate)	3 to 5 h	Chewable tablets, tablets (Ritalin), solution (Methylin)	Oral	Twice daily to 3 times daily	<p>The chewable tablets should be taken with at least 8 ounces (a full glass) of water or other fluid.</p> <p>The ER tablets may be used in place of the IR tablets when the 8-hour dosage of the ER product corresponds to the titrated 8-hour dosage of the IR products.</p> <p>The ER tablets must be swallowed whole and never crushed or chewed.</p>
Methylphenidate ER	3 to 8 h	Tablets			
Aptensio XR (methylphenidate ER)	12 h	Capsules	Oral	Daily in the morning	<p>The capsules may be taken whole or they can be opened and sprinkled onto applesauce; the applesauce should be consumed immediately and it should not be chewed.</p> <p>The dose of a single capsule should not be divided.</p>

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
Concerta (methylphenidate ER)	10 to 12 h	Tablets	Oral	Daily in the morning	The tablets should not be chewed or crushed.
Methylphenidate ER					Note: An FDA analysis of methylphenidate ER products manufactured by UCB/Kremers (formerly Kudco) and Mallinckrodt indicated that in some individuals, they may deliver the drug in the body at a slower rate during the 7- to 12-hour range. As a result, the FDA changed the therapeutic equivalence of these products from AB to BX. Because these manufacturers have subsequently failed to demonstrate that their products are bioequivalent to the brand-name reference drug, the FDA proposes to withdraw their approval (FDA 2016).
Cotempla XR-ODT (methylphenidate ER)	12 h	Orally disintegrating tablets	Oral	Daily in the morning	As soon as the blister pack is opened, the tablet should be placed on the patient's tongue and allowed to disintegrate without chewing or crushing. The tablet will disintegrate in saliva so that it can be swallowed.
Metadate CD (methylphenidate ER)	8 to 12 h	Capsules	Oral	Daily in the morning	The capsule may be swallowed whole or it may be opened and



Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					the contents sprinkled onto a small amount (tablespoon) of applesauce and given immediately. The capsule contents must not be crushed or chewed.
QuilliChew ER (methylphenidate ER)	12 h	Chewable tablets	Oral	Daily in the morning	
Quillivant XR (methylphenidate ER)	12 h	Suspension	Oral	Daily in the morning	The bottle of Quillivant XR should be shaken vigorously for 10 seconds prior to administration.
Ritalin LA (methylphenidate ER)	8 to 12 h	Capsules	Oral	Daily in the morning	The capsule may be swallowed whole or may be administered by sprinkling the capsule contents on a small amount of applesauce; the contents should not be crushed, chewed, or divided. The mixture should be consumed immediately.
Daytrana (methylphenidate transdermal system)	10 to 12 h	Transdermal system	Transdermal		The patch should be applied 2 hours before an effect is needed and removed within 9 hours. It may be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear.
<b>Non-stimulants</b>					
Strattera (atomoxetine)	24 h	Capsules	Oral	Daily in the morning or divided dose in the morning and late/afternoon early evening	Dosage adjustment is recommended for patients with moderate or severe hepatic insufficiency.  The capsules are not

Drug	Duration of action*	Available Formulations	Route	Usual Recommended Frequency	Comments
					intended to be opened and should be taken whole.
Kapvay (clonidine ER)	12 h	Tablets	Oral	Daily at bedtime or twice daily divided doses.	With twice daily dosing, either an equal or higher split dosage should be given at bedtime.  The tablets should not be crushed, chewed, or broken prior to swallowing.  The initial dosage should be based on the degree of renal impairment.
Intuniv (guanfacine ER)	8 to 24 h	Tablets	Oral	Daily in the morning or evening	The tablets should not be crushed, chewed, or broken prior to swallowing.  It may be necessary to reduce the dosage in patients with significant renal and hepatic impairment.

See the current prescribing information for full details

\*References: Prescribing information for individual products, *Medical Letter 2015, Pharmacist's Letter 2016, Krull 2017e*

## CONCLUSION

- Both CNS stimulants and non-stimulants may be used for the treatment of ADHD. In general, stimulants are first-line treatment due to their superior efficacy. Clinical evidence suggests that methylphenidate and amphetamines are equally efficacious, but some patients may respond to one stimulant and not the other. Various short-, intermediate- and long-acting formulations (eg, tablets/capsules, chewable/orally disintegrating tablets, solution/suspension, transdermal patch) are available to provide a range of dosing options. Although non-stimulants such as atomoxetine and alpha<sub>2</sub>-adrenergic agonists have smaller effect sizes, they may be used in patients who have failed or are intolerant to stimulants or when there is concern about possible abuse or diversion. The alpha<sub>2</sub>-adrenergic agonists are approved both as monotherapy and as adjunctive therapy to stimulants, and they have been shown to improve both tic and ADHD symptoms in patients with comorbid tic disorder.
  - Current consensus clinical guidelines for the treatment of children and adolescents with ADHD recommend that stimulants are highly effective for reducing core symptoms of ADHD in children (*AACAP 2007; AAP 2011*).
- Ultimately, the choice of the initial agent for treatment of ADHD depends upon various factors such as: duration of desired coverage; ability of the child to swallow pills or capsules; coexisting tic disorder (use of alpha<sub>2</sub>-adrenergic agonists may be warranted); potential AEs, history of substance abuse in the patient or household member (eg, avoid stimulants or use stimulants with less potential for abuse [eg, lisdexamfetamine, osmotic-release preparation, methylphenidate patch]; and preference of the patient and parent/guardian (*Krull 2017e*).
- Various stimulants are indicated for treatment of narcolepsy and are generally considered to be second-line agents after modafinil/armodafinil due to their sympathomimetic AEs (*Scammell 2017*).

- Lisdexamfetamine is the only FDA-approved drug indicated for the treatment of moderate to severe BED, with demonstrated efficacy in reduction of mean binge days per week vs. placebo. Direct comparison trials between lisdexamfetamine and other drugs used off-label to treat BED are lacking.

## REFERENCES

- Adderall [package insert], Horsham, PA: Teva Select Brands; December 2016.
- Adderall XR [package insert], Lexington, MA: Shire US Inc.; January 2017.
- Adzenys XR-ODT [package insert], Grand Prairie, TX: Neos Therapeutics, Inc.; January 2017.
- Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force On Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. *World J Biol Psychiatry*. 2011;12(6):400-443.
- Aptensio XR [package insert], Coventry, RI: Rhodes Pharmaceuticals, L.P.; January 2017.
- Brownley KA, Berkman ND, Peat CM, et al. Binge-eating disorder in adults: A systematic review and meta-analysis. *Ann Intern Med*. 2016;165(6):409-420.
- Bukstein O. Attention deficit hyperactivity disorder in adults: Epidemiology, pathogenesis, clinical features, course and diagnosis. UpToDate Web site. 2017. <http://www.uptodate.com>. Updated November 3, 2016. Accessed June 23, 2017.
- Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. *JAMA*. 2016;315(18):1997-2008.
- Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Efficacy, safety, and tolerability of an extended-release orally disintegrating methylphenidate tablet in children 6-12 years of age with attention-deficit/hyperactivity disorder in the laboratory classroom setting. *J Child Adolesc Psychopharmacol*. 2017;27(1):66-74.
- Concerta [package insert], Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2017.
- Cotempla XR-OD [package insert], Grand Prairie, TX: Neos Therapeutics Brands, LCC; June 2017.
- Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med*. 2011;365(20):1896-1904.
- Cunill R, Castells X, Tobias A, Capellà D. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression. *Pharmacoepidemiol Drug Saf*. 2013;22(9):961-969.
- Daytrana [package insert], Miami, FL: Noven Therapeutics, LLC; January 2017.
- Desoxyn [package insert], Lebanon, NJ: Recordati Rare Diseases Inc.; May 2017.
- Dexedrine Spansule [package insert], Horsham, PA: Amedra Pharmaceuticals LLC; May 2017.
- Drug scheduling. Drug Enforcement Administration Web site. <http://www.dea.gov/druginfo/ds.shtml>. Accessed June 23, 2017.
- Drugs@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2017. Available from: <http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>. Accessed June 23, 2017.
- Drugs for ADHD. *Med Lett Drugs Ther*. 2015;57(1464):37-40.
- Dyanavel XR [package insert], Monmouth Junction: Tris Pharma, Inc.; May 2017.
- Evekeo [dossier], Atlanta, GA: Arbor Pharmaceuticals, LLC; 2015.
- Evekeo [package insert], Atlanta, GA: Arbor Pharmaceuticals, LLC; September 2016.
- Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. *MedGenMed*. 2006;8(4):4.
- Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. *Eur Child Adolesc Psychiatry*. 2010a;19(4):353-364.
- Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. *J Clin Psychiatry*. 2010b;71(6):754-763.
- Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. *N Engl J Med*. 2014;370(9):838-846.
- Focalin [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; January 2017.
- Focalin XR [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; January 2017.
- Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL. A phase 3, multicenter, open-label, 12-month extension safety and tolerability trial of lisdexamfetamine dimesylate in adults with binge eating disorder. *J Clin Psychopharmacol*. 2017 ;37(3):315-322.
- Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. *J Am Acad Child Adolesc Psychiatry*. 2006;45(11):1284-1293.
- Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*. 2011;306(24):2673-2683.
- Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):153-173.
- Intuniv [package insert], Lexington, MA: Shire US Inc.; July 2016.
- Jadad AR, Boyle M, Cunningham C, Kim M, Schachar R. Treatment of attention-deficit/hyperactivity disorder. *Evid Rep Technol Assess (Summ)*. 1999;(11):i-viii, 1-341.
- Kapvay [package insert], St. Michel, Barbados: Concordia, Pharmaceuticals, Inc.; August 2016.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis. UpToDate Web site. 2017a. <http://www.uptodate.com>. Updated June 4, 2017. Accessed June 23, 2017.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis. UpToDate Web site. 2017b. <http://www.uptodate.com>. Updated March 28, 2017. Accessed June 23, 2017.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis. UpToDate Web site. 2017d. <http://www.uptodate.com>. Updated June 14, 2017. Accessed June 23, 2017.
- Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate Web site. 2017e. <http://www.uptodate.com>. Updated June 1, 2016. Accessed June 23, 2017.

- Krull KR. Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents. UpToDate Web site. 2017c. <http://www.uptodate.com>. Updated February 23, 2017. Accessed June 23, 2017.
- Li Y, Gao J, He S, Zhang Y, Wang Q. An evaluation on the efficacy and safety of treatments for attention deficit hyperactivity disorder in children and adolescents: a comparison of multiple treatments. *Mol Neurobiol*. 2016 Oct 13.[Epub ahead of print].
- McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials. *Neuropsychopharmacology*. 2016;41(5):1251-1260.
- Metadate CD [package insert], Smyrna, GA: UCB; January 2017.
- Methylin oral solution [package insert], Florham Park, NJ: Shionogi Inc.; September 2016.
- Methylphenidate chewable tablets [package insert]; Somerset, NJ: GAVIS Pharmaceuticals, LLC; December 2015.
- Methylphenidate ER [package insert], Newtown, PA: KVK-Tech, Inc.; July 2015.
- Methylphenidate hydrochloride extended-release tablets (generic Concerta) made by Mallinckrodt and Kudco. FDA Web site. November 4, 2016. <http://www.fda.gov/Drugs/DrugSafety/ucm422568.htm>. Accessed June 23, 2017.
- Morgenthaler TI, Kapur VK, Brown T, et al; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. *Sleep*. 2007;30(12):1705-1711.
- Mydayis [package insert], Lexington, MA: Shire US Inc.; June 2017.
- Newcorn JH, Kratochvil CJ, Allen AJ, et al; Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. *Am J Psychiatry*. 2008;165(6):721-730.
- Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Food and Drug Administration Web site. <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>. Accessed June 23, 2017.
- PL Detail-Document, Comparison of ADHD medications. *Pharmacist's Letter/Prescriber's Letter*. March 2016
- PL Detail-Document, Management of ADHD: When a stimulant is not enough. *Pharmacist's Letter/Prescriber's Letter*. April 2015.
- Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2007;46(7):894-921.
- Practice parameter for the assessment and treatment of children and adolescents with tic disorders. *J Am Acad Child Adolesc Psychiatry*. 2013;52(12):1341-1359.
- ProCentra [package insert], Newport, KY: Independence Pharmaceuticals, LLC; February 2017.
- Punja S, Shamsseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. *Cochrane Database Syst Rev*. 2016;2:CD009996.
- QuillChew ER [package insert], New York, NY: Pfizer, Inc.; March 2017.
- Quillivant XR [package insert], New York, NY: Pfizer, Inc.; June 2017.
- Ritalin [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation; January 2017.
- Ritalin LA [package insert], East Hanover, NJ: Novartis Pharmaceuticals Corporation.; January 2017.
- Scammell TE. Treatment of narcolepsy in adults. UpToDate Web site. 2017. <http://www.uptodate.com>. Updated June 21, 2017. Accessed June 23, 2017.
- Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. *J Am Acad Child Adolesc Psychiatry*. 2014;53(2):174-187.
- Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). *Cochrane Database Syst Rev*. 2015;11:CD009885.
- Strattera [package insert], Indianapolis, IN: Lilly USA, Inc.; May 2017.
- Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. *J Affect Disord*. 2015;178:149-159.
- Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. *Pediatrics*. 2011;128(5):1007-1122.
- Vyvanse [package insert], Lexington, MA: Shire US Inc.; May 2017.
- Yager J, Devlin MF, Halmi KA, et al. Guideline watch (August 2012): Practice guideline for the treatment of patients with eating disorders, 3rd edition. Psychiatry Online Web site. <http://psychiatryonline.org/guidelines>. Accessed June 23, 2017.
- Yager J, Devlin MF, Halmi KA, et al. Practice guideline for the treatment of patients with eating disorders, 3rd edition (2006). Psychiatry Online Web site. <http://psychiatryonline.org/guidelines>. Accessed June 23, 2017.
- Zenedi [package insert], Atlanta, GA: Arbor Pharmaceuticals, LLC; February 2017.